Impact__O summary:__O During__O the__O REF__B-ORG period,__O employee__O numbers__O at__O Q__B-ORG Chip__I-ORG increased__O from__O 10__O to__O 29__O (up__O 180%),__O there__O were__O 5__O patent__O filings__O and__O there__O was__O &#163;7.5M__O of__O new__O investment__O (75%__O of__O the__O total__O company__O investment)__O over__O 6__O funding__O rounds__O [5.1],[5.2].__B-ORG
Access__O to__O new__O miniaturised__O industrial__O bioprocessing__O equipment__O and__O new__O drug__O delivery__O techniques__O (currently__O under__O trials)__O were__O sold__O to__O top__O pharmaceutical__O companies__O for__O improved__O quality__O of__O life__O through__O cancer__O treatment.__O
Revenues__O from__O four,__O staged__O payment,__O six-figure__O value__O contracts__O [5.1],[5.2]__O have__O risen__O from__O &#163;17k__B-ORG in__O 2010,__O &#163;297k__O in__O 2011__O to__O &#163;578k__O in__O 2012.__O
Company__O growth:__O During__O the__O REF__B-ORG period__I-ORG Q__I-ORG Chip__I-ORG has__O developed__O a__O bio-encapsulation__O and__O drug__O delivery__O platform__O that__O enables__O companies__O to__O extend__O product__O life__O cycles__O and__O deliver__O complex__O bio-therapeutics__O [5.3].__O
It__O currently__O manufactures__O drug-loaded__O microspheres,__O mainly__O for__O pharmaceutical__O industries.__O
Q__O Chip__O aims__O to__O improve__O patient__O compliance__O and__O experience,__O and__O improve__O therapeutic__O performance__O through__O the__O development__O of__O long-acting,__O injectable__O therapeutics__O using__O its__O proprietary__O platform,__O Q-SpheraTM__B-ORG [5.3].__O
This__O breakthrough__O microsphere__O manufacturing__O and__O formulation__O system__O is__O compatible__O with__O small__O molecules,__O peptides__O and__O complex__O biologicals.__O
With__O its__O commercial__O client__O partners,__O and__O with__O guidance__O from__O its__O scientific__O advisory__O board__O (on__O which__O Barrow__B-ORG sits),__O Q__B-ORG Chip__I-ORG is__O developing__O point-of-care__O clinical__O data__O with__O three__O different__O molecules__O encapsulated__O within__O drug-eluting,__O polymeric__O microspheres.__O
Q__O Chip__O is__O licensing__O the__O microsphere__O production__O and__O sale__O via__O these__O client__O partners__O who,__O through__O their__O own__O existing__O global__O marketplace__O presence,__O are__O taking__O the__O products__O to__O market.__O
Q__O Chip__O has__O five__O injectable,__O encapsulated__O drug__O formulations__O in__O its__O therapeutics__O pipeline,__O including__O Q-Goserelin__B-ORG and__O Q-Leuprolide__B-ORG for__O the__O treatment__O of__O breast__O and__O prostate__O cancer,__O Q-Insulin__O for__O diabetes__O therapy,__O Q-Octreotide__O for__O acromegaly,__O and__O a__O new__O formulation__O of__O monoclonal__O antibodies__O for__O a__O confidential__O application__O [5.1].__O
All__O have__O substantial__O existing__O markets.__O
For__O instance,__O Leuprolide__O and__O Octreotide__B-MISC products__O achieved__O annual__O sales__O of__O around__O $1800M__O and__O $1200M__O in__O 2010;__O this__O is__O out__O of__O a__O total__O global__O market__O for__O injectable__O therapeutics__O of__O $49B.__O
During__O 2011,__O Q__O Chip__O signed__O four__O separate__O multi-year__O R&amp;D__B-MISC deals__O with__O international__O pharmaceutical__O companies__O [5.1].__O
Two__O of__O these__O contracts__O are__O with__O those__O in__O the__O top__O five__O global__O pharmaceutical__O industries.__O
Q__O Chip__O has__O developed__O a__O contractual__O relationship__O with__O leading__O biotechnology/pharmaceutical__O company,__O ARTES__O Biotechnology__O GmbH__O [5.4],__O for__O the__O sustained__O release__O of__O therapeutic__O protein__O interferon__O alpha__O 2__O (using__O microspheres)__O to__O treat__O chronic__O hepatitis__O B__O and__O C.__B-PER A__O third__O contract__O is__O with__O a__O UK__B-LOC pharmaceutical__O company,__O a__O fourth__O with__O a__O mid-sized__O European__B-MISC pharmaceutical__O company__O [5.1]__O (contractually,__O other__O company__O names__O cannot__O be__O disclosed).__O
Further__O technical__O development:__O During__O the__O REF__B-ORG period__O Barrow__B-ORG has__O continued__O to__O be__O instrumental__O in__O determining__O the__O on-going__O evolution__O of__O the__O technology__O developed__O through__O the__O underlying__O research__O into__O Q__B-ORG Chip's__I-ORG expanding__O range__O of__O products.__O
He__O has__O also__O supported__O the__O company__O as__O chair__O and__O co-chair__O of__O Q__B-ORG Chip's__I-ORG Scientific__I-ORG Advisory__I-ORG Board.__I-ORG
His__O involvement__O has__O enabled__O access__O to__O his__O TSB__O funded__O metaFAB__O facility__O for__O HPLC-MS__B-ORG and__O femtosecond__O laser__O micromachining,__O and__O has__O enabled__O additional__O two-way__O development__O contracts__O between__O the__O University__B-ORG (Professor__I-ORG Steve__I-ORG Dunnet,__I-ORG Dr.__I-ORG Peter__B-PER Kille)__I-PER and__O Q__B-ORG Chip.__I-ORG
The__O latter__O contracts__O developed__O cell-encapsulation__O capabilities__O for__O the__O company,__O using__O its__O core__O microsphere__O production__O technology.__O
Since__O Q__O Chip's__O inception,__O there__O has__O been__O significant__O process__O development__O and__O intellectual__O property__O protection,__O through__O five__O patents,__O based__O on__O its__O collaborative__O research__O programme.__O
Microspheres__O are__O produced__O using__O a__O hybrid__O of__O the__O original__O IP__O with__O new__O geometries__O and__O sub-systems.__O
This__O happens__O at__O a__O greater__O rate,__O with__O less__O solvent__O waste,__O using__O automated,__O industry-ready__O bespoke__O equipment,__O also__O manufactured__O by__O Q__B-PER Chip.__I-PER
The__O Q-Sphera__B-MISC manufacturing__O process__O leads__O to__O environmental__O improvements__O and__O is__O now__O much__O `greener'__O than__O current__O methods__O because__O (i)__O it__O operates__O without__O Class__B-PER II__I-PER halogenated/hazardous__O solvents__O (e.g.__O
dichloromethane/chloroform),__O (ii)__O it__O uses__O &gt;80%__B-MISC aqueous__O solvents__O (so__O waste__O may__O be__O recycled__O to__O remove__O Class__B-PER III__I-PER solvents__O such__O as__O DMSO,__B-ORG alcohols),__O (iii)__O it__O is__O far__O more__O efficient__O than__O current__O methods__O since__O there__O is__O no__O need__O for__O size-fractionation__O (no__O wastage__O of__O intermediary__O product__O since__O there__O is__O none),__O and__O (iv)__O the__O unique,__O highly__O miniaturised,__O production-on-demand__O processing__O equipment__O (manufactured__O by__O Q__O Chip)__B-PER sits__O on__O a__O desk,__O rather__O than__O occupying__O a__O building__O [5.1].__O
In__O 2011,__O through__O a__O &#163;3.6M__O external__O investor__O round,__O the__O Q__O Chip__O BV__O European__B-MISC manufacturing__O subsidiary__O was__O founded__O as__O a__O cGMP__O sterile__O pharmaceutical__O production__O facility__O at__O Geleen,__B-LOC near__O Maastricht,__B-LOC with__O initially__O three__O FTE__B-ORG staff__O [5.5].__O
In__O 2012,__O the__O company__O was__O awarded__O a__O TSB__B-ORG grant__O of__O &#163;250k__B-MISC towards__O the__O cost__O of__O developing__O its__O innovative,__O scaled-up,__O sustained-release__O pharmaceutical__O manufacturing__O process__O and__O production__O equipment__O [5.1].__O
Company__O investment:__O To__O provide__O context__O to__O the__O company__O investments__O during__O the__O REF__B-ORG period,__O it__O is__O valuable__O to__O know__O that__O before__O the__O REF__B-ORG period,__O the__O business__O secured__O first__O round__O funding__O from__O the__O E-Synergy__B-MISC investor__O syndicate__O in__O 2004__O (lead__O investor__O John__B-PER Moulton),__I-PER with__O a__O corresponding__O second__O closing__O IP-equity__O swap__O with__O Cardiff__B-ORG University,__I-ORG which__O now__O holds__O about__O 3%__O equity.__O
Since__O its__O incorporation__O in__O 2003,__O Q__O Chip__O has__O attracted__O investment__O of__O &#163;10.4M__B-ORG over__O 12__O funding__O rounds__O from__O angel__O and__O institutional__O investors,__O has__O over__O 57__O shareholders,__O with__O 29__O FTE__B-ORG staff__O who__O have__O contributed__O to__O employment__O in__O Wales__B-LOC [5.6].__O
During__O 2011-12,__O existing__O shareholders,__O including__O Disruptive__B-ORG Capital__I-ORG Finance__I-ORG and__O Finance__B-ORG Wales,__I-ORG were__O joined__O by__O venture__O capitalist__O Jon__B-PER Moulton__I-PER (founder__O of__O Better__B-LOC Capital)__I-LOC [5.7]__O and__O industrial__O entrepreneur__O Sir__O Harry__B-PER Solomon,__I-PER in__O two__O &#163;5.6M__B-MISC Series__I-MISC C__O financing__O rounds__O led__O by__O Limburg__B-PER Ventures__I-PER and__O Nedermaas__B-ORG Hightech__I-ORG Ventures__I-ORG [5.7],[5.8].__O
Q__O Chip__O uses__O these__O funds__O to__O increase__O production__O by__O scaling-up__O manufacturing__O development__O of__O encapsulated__O drugs__O for__O prostate__O cancer__O and__O acromegaly.__O
Finally,__O in__O 2011-12__O EPSRC__B-ORG undertook__O a__O healthcare__O economic__O IMPACT__O Study__O on__O Q__O Chip,__O since__O its__O origins__O were__O based__O on__O EPSRC-funded__B-MISC research__O (IMPACT__B-ORG summarised__O in__O [5.9]__O and__O [5.10]).__O
